Genprex Announces New Research Identifying TROP2 as a Potential Predictive Biomarker to Reqorsa® Gene Therapy in Lung Cancer
PR Newswire•04/11/2026•07:00 ET
0
Key Highlights
- ➤Low TROP2 expression associated with REQORSA resistance across NSCLC models
- ➤50% of 10 cell lines and 50% of 12 organoid models showed primary resistance
- ➤Pretreatment patient biopsies supported TROP2 expression’s association with treatment response
- ➤TROP2 modulation altered TUSC2-induced cancer cell death in experiments
- ➤Prospective clinical evaluation remains necessary to validate TROP2’s predictive utility
Expert Statements
Ryan Confer, President and Chief Executive Officer of Genprex
“Discovering an applicable biomarker of response is a meaningful step toward a more precise approach to treating lung cancer with REQORSA”
Ryan Confer, President and Chief Executive Officer of Genprex
“These data show that low TROP2 expression was associated with primary resistance across multiple preclinical models, and this was supported by analysis of patient biopsies from a clinical trial.”
Ryan Confer, President and Chief Executive Officer of Genprex
“If confirmed in further studies, TROP2 could not only help us enhance our clinical trials by recruiting and selecting more applicable patients, but, more importantly, benefit future patients by ultimately delivering potentially more effective, personalized treatment options.”
Ryan Confer, President and Chief Executive Officer of Genprex
“This work reflects our commitment to a precision-medicine approach to treating lung cancer.”
Genprex Announces New Research Identifying TROP2 as a Potential Predictive Biomarker to Reqorsa® Gene Therapy in Lung Cancer PR Newswire
Research to be Presented at the 2026 EORTC-NCI-AACR Symposium Links TROP2 Expression to Treatment Response and Explores its Role in Treatment Sensitivity
Get started
Create a free account to read the full story.